01952 EVEREST MED-B
- 24.350
- -1.250-4.88%
EVEREST MED-B News
The world's first IgA nephropathy treatment was successfully prescribed for resistance to the drug fukang, and the price per bottle was only one-tenth of the US
With the successful dispensing of Nifukang's first prescription, the cost of its treatment attracted widespread attention in the market.
Featured announcements | Tencent's Q1 adjusted net profit increased 54% year on year; Ali's adjusted net profit for the fourth fiscal quarter fell 11% year on year
China Railway Construction won bids for several projects totaling more than 60 billion yuan; Mingchuang Premium: Q1 adjusted net profit of 617 million yuan, an increase of 27.7% over the previous year.
Genting Xinyao (01952) announced that the world's first prescription for IgA nephropathy is resistant to the drug fukang in mainland China and opens a new era of IgA nephropathy treatment
Zhitong Finance App learned that Genting Xinyao (01952) is a biopharmaceutical company focusing on R&D, clinical development, manufacturing and commercialization of innovative drugs and vaccines. Today, it was announced that Nefucan (budesonide enteric capsules, NEFECON) has successfully implemented its first prescription in China, marking that the world's first drug for IgA nephropathy has officially benefited patients in mainland China, opening a new chapter in the treatment of the causes of IgA nephropathy in China. China is one of the countries with the highest incidence of primary glomerular diseases in the world, and as a common primary glomerular disease, IgA nephropathy accounts for about 35% to 50%. studying
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Genting Xinyao Announces the World's First IgA Renal Treatment Drug Endurance in Mainland China, Launching a New Era of IgA Renal Treatment
SHANGHAI, MAY 14, 20242/BEAUTY COMMUNICATION/ -- GÜNDING XINYAO (HKEX 1952.HK), A BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIVE DRUG AND VACCINE R&D, CLINICAL DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION, TODAY ANNOUNCED THAT NAECHANG (PUDINE NEFECON CAPSULE) HAS SUCCESSFULLY LANDED THE FIRST PRESCRIPTION IN CHINA. Encouraging the launch of the world's first IgA kidney disease treatment drug to patients in mainland China, it opens a new chapter in the treatment of IgA kidney disease in China. China is one of the countries with the highest incidence of primary kidney disease in the world, as a common primary renal cell
Genting Xinyao: Naifukang officially commercialized in mainland China
Genting Xinyao B announced that NEFECON (NEFECON) was officially commercialized in mainland China on May 14, 2024, and the first prescription was successfully issued by an Internet hospital. This marks that the world's first drug for IgA nephropathy has officially begun to benefit Chinese patients, opening a new chapter in the treatment of the causes of IgA nephropathy in China. The company will adopt innovative joint promotion methods between traditional hospitals and internet hospitals, which is expected to greatly enhance the accessibility of patients across the country and improve their medication compliance. Nefukang received China's national medicine in November 2023
Hong Kong Stock Afternoon Review | Tech Index rose nearly 1%, TechNet stocks and biotech stocks rose higher, Bilibili rose more than 6%, and Laikai Pharmaceuticals rose more than 12%
Auto stocks rose more than 6%; Great Wall Motor rose more than 6%; NIO and Zero Sports Auto rose more than 5%; many coal stocks fell sharply, Yankuang Energy fell more than 6%, and Shougang resources fell nearly 6%.
Genting Xinyao (01952) announced that the Macau Drug Administration of China approved the marketing license application for a new drug using itramod (VELSIPITY) for the treatment of moderate to severe active ulcerative colitis
Genting Xinyao (01952) is a biopharmaceutical company focusing on R&D, clinical development, manufacturing and commercialization of innovative drugs and vaccines. Today, the Macau Special Administrative Region Drug Administration has officially approved the marketing license application for VELSIPITY (etrasimod) for the treatment of adult patients with moderate to severe active ulcerative colitis.
Express News | Genting Xinyao: Itramod's new drug marketing application approved in Macau
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Everest Medicines' Loss Widens in 2023
Everest Medicines' (HKG:1952) net loss attributable to equity holders widened to 844.5 million yuan in the year ended Dec. 31, 2023, from a loss of 247.3 million yuan a year ago, according to a Wednes
雲頂新耀-B：2023年度報告
Tencent recorded the biggest one-day increase in 10 months! The public offering group went south, and Zhang Kun and his team “overmatched” Hong Kong stocks
In the context of public fund giants collectively increasing their positions, Tencent Holdings recorded the biggest one-day increase in the last 10 months.
A quick look at the Hong Kong market | The three major indices have risen one after another. Technet stocks have generally risen, Tencent and Meituan have risen by more than 5%; Ideal has fallen by more than 8%
Many coal stocks fell sharply; Mongolian coking coal and China Coal Energy fell more than 6%; petroleum stocks fell, CNOOC Services fell more than 3%, and CNPC fell nearly 3%.
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 8%, and many positive results of Nifukang appeared in WCN2024
Genting Xinyao B (01952) rose more than 8%. As of press release, it had risen 8.12% to HK$23.3, with a turnover of HK$67.237 million.
Hong Kong Stock Afternoon Review | The three major indices fell sharply, auto stocks fell, and Ideal Auto fell by more than 7%
Technology and network stocks generally fell; Xiaomi fell more than 4%, Meituan fell nearly 4%; shipping stocks rose higher, Pacific Shipping rose more than 9%, and COSCO Haineng rose more than 5%.
Hong Kong Stock Afternoon Review | The three major indices continued to weaken, the Tech Index fell nearly 3%, and Tech Net stocks and auto stocks generally fell
Biotech stocks fell collectively; Kingsley Biotech fell more than 4%; Genting Xinyao fell by more than 3%; gaming stocks fell, with Aobo Holdings and Sands China falling more than 4%; insurance stocks fell by more than 3%; and China Ping An fell nearly 2%.
Hong Kong Stock Afternoon Review | The three major indices declined, TechNet stocks and gold stocks fell, NetEase fell nearly 3%, and Zhaojin Mining fell nearly 9%
Biotech stocks fell, with Genting Xinyao falling more than 6%, and Kingsley Biotech falling nearly 5%; auto stocks fell by many stocks, Xiaopeng Motors fell nearly 4% and Geely fell nearly 3%; petroleum stocks improved, and CNPC rose more than 2%.
Changes in Hong Kong stocks | Genting Xinyao-B (01952.HK) rose more than 6% in the intraday period and surged more than 20% this week, the IgA nephropathy market reappeared with a 10-billion takeover
Genting Xinyao B (01952.HK) rose more than 6% in the intraday period, with a cumulative increase of more than 20% this week. As of press release, it rose 4.1% to HK$26.65, with a turnover of HK$87.213,400.
Analysis
Price Target
No Data
